Skip to main content

Month: August 2025

Solo Brands, Inc. Announces Second Quarter 2025 Results

Strategic Foundation Set to Build a Structurally Smaller, Profitable Company: Bottom-line Focus Generates Positive Second Quarter Cash from Operations of nearly $11 million GRAPEVINE, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) — Solo Brands, Inc. (NYSE: SBDS)(1) (“Solo Brands” or “the Company”) a leading portfolio of lifestyle brands (Solo Stove, Chubbies, Isle and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three and six months ended June 30, 2025. “For the second quarter, we are pleased to mark significant milestones, including our debt refinancing, removal of the going concern disclaimer and reinstatement of the trading of our Class A common stock, trading under a new ticker symbol SBDS, on the NYSE. In addition, we are making meaningful strides in our transformation...

Continue reading

FLUENT Corp. Provides Management Update

TAMPA, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) — FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), a leading national cannabis brand, announces that Robert Beasley has provided notice of his resignation from his positions as Chief Executive Officer and a Director of FLUENT, effective August 8, 2025, in furtherance of his and the Company’s mutual determination that a leadership change is in the best interest of the Company as it advances its strategic priorities. William Smith, Executive Chair of the board of directors of the Company (the “Board”), commented, “On behalf of the Board and the entire Company, I would like to extend our sincere gratitude to Robert for his leadership and dedication during his time with the Company. His contributions have been instrumental in positioning us for future growth and sustainable...

Continue reading

IREN July 2025 Monthly Update

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (together with its subsidiaries, “IREN” or “the Company”) today published its monthly update for July 2025. July HighlightsRecord monthly revenue and hardware profit3 AI Cloud expanded with 2.4k NVIDIA B200/B300 GPUs Initial B200 shipment completed and fully contracted 50MW Horizon 1 liquid-cooled AI data center on track for Q4’25 Mackenzie fiber upgrade complete, further enhancing our ability to support continued growth of AI Cloud beyond Prince George 1,400MW Sweetwater 1 civil and electrical works continuingKey Metrics Jul 25 Jun 25Bitcoin Mining    Average operating hashrate 45.4 EH/s 41.1 EH/sBitcoin mined4 728 BTC 620 BTCRevenue per Bitcoin mined $114,891 $105,730Net electricity cost per Bitcoin mined2 ($27,976) ($26,259)Revenue $83.6m $65.5mNet...

Continue reading

Stack Capital Group Inc. Reports Q2-2025 Financial Results

TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A) today announced its financial results for the quarter ended June 30, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary:As at June 30, 2025, Book Value per Share (BVpS) of the Company was $14.34, compared with $12.06 as at March 31, 2025. Stack Capital had its first portfolio investment, CoreWeave (an AI hyper-scaler), go public on March 28, 2025, an exciting milestone for both the Company and CoreWeave. As of June 30, 2025, the Company marked up its investment in CoreWeave by US$25.7 million to reflect its closing price of US$163.06. During Q2-2025, The Company invested an additional US$3M into SpaceX. Following the quarter-end, SpaceX’s valuation...

Continue reading

First Quantum Minerals Announces Cash Tender Offer to Purchase Any and All of Its Outstanding 6.875% Senior Notes Due 2027

(In United States dollars, except where noted otherwise) TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (the “Company” or “First Quantum”) (TSX: FM) today announced that it has commenced an offer to purchase for cash (the “Tender Offer”) any and all of its outstanding 6.875% Senior Notes due 2027 (the “Notes”) from holders of the Notes (“Holders”), as further described in the offer to purchase dated the date hereof (the “Offer to Purchase”) and the related Notice of Guaranteed Delivery. The Tender Offer will expire at 5:00 pm, New York City time, on August 12, 2025 (such date, as may be extended, the “Expiration Date”). The consideration for each $1,000 principal amount of Notes tendered prior to the Expiration Date and accepted for purchase pursuant to the Tender Offer shall be the “Notes Consideration”...

Continue reading

Kornit Digital Reports Second Quarter 2025 Results

Second quarter revenues of $49.8 million, in line with previous guidance Second quarter GAAP net loss of $7.5 million; non-GAAP net income of $1.2 million Continued to generate cash from operations Reported annual recurring revenue from AIC contracts of $18.9 million, reflecting continued adoption of this new model, particularly from screen-printing customers.ROSH-HA`AYIN, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a global leader in sustainable, on-demand, digital fashion and textile production technologies, today reported results for the second quarter ended June 30, 2025. “We delivered second quarter results within our guidance range in a challenging market environment, reflecting ongoing progress in transforming our business toward recurring revenue and long-term...

Continue reading

Purple Biotech Reports Second Quarter 2025 Financial Results

Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody targeting novel tumor associated antigen, 5T4, advances toward first-in-human clinical trials, with IND submission expected in 2026 Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025 NT219 Phase 2 study in head and neck cancer initiated in June 2025 REHOVOT, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today financial results...

Continue reading

Sprott Announces Second Quarter 2025 Results

TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the three and six months ended June 30, 2025. Management commentary “Sprott’s Assets Under Management (“AUM”) were $40 billion as at June 30, 2025, up 14% from $35.1 billion as at March 31, 2025 and up 27% from $31.5 billion as at December 31, 2024,” said Whitney George, Chief Executive Officer of Sprott. “During the quarter we benefited from market value appreciation across our product suite, driven by rising precious metals and uranium prices and strong performance in our managed equities segment. We also reported $1.2 billion in net sales during the quarter, concentrated largely in our physical trusts.” “We are pleased with how our balanced product offerings...

Continue reading

Brink’s Delivers Strong Second-Quarter Results Exceeding Top End of Guidance for Revenue, Operating Profit, and EBITDA

Record Second-Quarter Operating Profit Margin as AMS/DRS Continue to Gain MomentumIncreasing Full-Year 2025 Revenue and EBITDA Expectations RICHMOND, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced second-quarter results. Mark Eubanks, president and CEO, said: “I am proud of our consistent execution and the delivery of another quarter of meaningful progress against our strategic priorities. We continue to grow higher-margin subscription-based AMS / DRS revenue, expand our profit margins, improve our cash conversion and return capital to shareholders. This was clear in our strong second quarter performance which exceeded the top end of our quarterly guidance for revenue,...

Continue reading

Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine

Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a new publication in the journal Vaccine, supporting the efficacy of its biodefense vaccine candidate, ATI-1701. The manuscript, titled, “Vaccination with a novel live attenuated strain of Francisella tularensis subsp. tularensis protects cynomolgus macaques against aerosol F. tularensis infection,” details studies showing robust and durable protection from lethal tularemia exposure in both rat and non-human primate models. ATI-1701,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.